Dr. Mehmet H. Kocoglu, MD

Dr. Kocoglu practices at University of Maryland Medical Center in Baltimore, Maryland, part of University of Maryland Medical System.

Dr. Kocoglu's NPI, 1114001138, was assigned on October 25, 2006. Dr. Kocoglu holds Maryland license D78398.

Dr. Kocoglu's primary practice is University of Maryland Medical Center, at 22 South Greene Street, Baltimore, MD 21201 in Baltimore City. The practice phone is (410) 328-8667.

Dr. Kocoglu's primary practice is University of Maryland Medical Center in Baltimore, Maryland, part of University of Maryland Medical System. Dr. Kocoglu is also affiliated with MedStar Franklin Square Medical Center. The medical group on file is University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC). Dmand AI also links Dr. Kocoglu to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kocoglu practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kocoglu's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Kocoglu's licenses on file in 2 states: Maryland and Arkansas.

CMS data shows 639 Medicare services from Dr. Kocoglu across 9 procedure codes in 2024, for 206 Medicare patients. Medicare paid $54,275 for them.

CMS counts 206 Medicare patients who saw Dr. Kocoglu in 2024. The largest group is 65 to 74, with 94 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 17% are also on Medicaid. Their average risk score is 3.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kocoglu's median patient age at 69, with 49% women.

In 2024, Dr. Kocoglu wrote 341 Medicare Part D claims for 48 patients. 90% of them were for generic drugs. CMS names the drug for 202 of them, across 9 drugs with 11 or more claims each, at $488,604 in total drug cost. In 2023, CMS named 235 claims across 13 drugs.

Dr. Kocoglu accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kocoglu as offering telehealth.

Dmand AI links 41 papers to Dr. Kocoglu, published from 2012 to 2025. 2024 was the busiest year, with 7. The most frequent topics are Multiple Myeloma, Immunotherapy, Adoptive and Receptors, Chimeric Antigen. Dr. Kocoglu has published most often in Blood. Dr. Kocoglu's most frequent co-authors are Aaron Paul Rapoport, MD, Djordje Atanackovic, MD and Jean A. Yared, MD.

Dmand AI links Dr. Kocoglu to 2 clinical trials, 2 of them phase 1 studies. 2 are still active or recruiting. Conditions studied include Kidney Failure, Chronic, Multiple Myeloma and Blood Protein Disorders. GlaxoSmithKline sponsors the most, 2.

CMS Open Payments shows 21 general payments to Dr. Kocoglu from 14 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 86% of the total. Amgen Inc. paid the most, $381.